186 related articles for article (PubMed ID: 32493992)
1. Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds.
Li Petri G; El Hassouni B; Sciarrillo R; Funel N; Mantini G; Zeeuw van der Laan EA; Cascioferro S; Avan A; Zucali PA; Zaffaroni N; Lagerweij T; Parrino B; Smid K; Deraco M; Granchi C; Braczko A; Smolenski RT; Matherly LH; Jansen G; Assaraf YG; Diana P; Cloos J; Peters GJ; Minutolo F; Giovannetti E
Br J Cancer; 2020 Aug; 123(4):644-656. PubMed ID: 32493992
[TBL] [Abstract][Full Text] [Related]
2. Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools.
Giovannetti E; Zucali PA; Assaraf YG; Funel N; Gemelli M; Stark M; Thunnissen E; Hou Z; Muller IB; Struys EA; Perrino M; Jansen G; Matherly LH; Peters GJ
Ann Oncol; 2017 Nov; 28(11):2725-2732. PubMed ID: 28945836
[TBL] [Abstract][Full Text] [Related]
3. Proton-coupled folate transporter as a biomarker of outcome to treatment for pleural mesothelioma.
Petri GL; Cascioferro S; Parrino B; Peters GJ; Diana P; Giovannetti E
Pharmacogenomics; 2018 Jul; 19(10):811-814. PubMed ID: 29916298
[No Abstract] [Full Text] [Related]
4. A specific inhibitor of lactate dehydrogenase overcame the resistance toward gemcitabine in hypoxic mesothelioma cells, and modulated the expression of the human equilibrative transporter-1.
Giovannetti E; Leon LG; Gómez VE; Zucali PA; Minutolo F; Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2016 Dec; 35(10-12):643-651. PubMed ID: 27906635
[TBL] [Abstract][Full Text] [Related]
5. Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia.
Maftouh M; Avan A; Sciarrillo R; Granchi C; Leon LG; Rani R; Funel N; Smid K; Honeywell R; Boggi U; Minutolo F; Peters GJ; Giovannetti E
Br J Cancer; 2014 Jan; 110(1):172-82. PubMed ID: 24178759
[TBL] [Abstract][Full Text] [Related]
6. The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer.
Matherly LH; Hou Z; Gangjee A
Cancer Chemother Pharmacol; 2018 Jan; 81(1):1-15. PubMed ID: 29127457
[TBL] [Abstract][Full Text] [Related]
7. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
8. Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma.
Reid G; Pel ME; Kirschner MB; Cheng YY; Mugridge N; Weiss J; Williams M; Wright C; Edelman JJ; Vallely MP; McCaughan BC; Klebe S; Brahmbhatt H; MacDiarmid JA; van Zandwijk N
Ann Oncol; 2013 Dec; 24(12):3128-35. PubMed ID: 24148817
[TBL] [Abstract][Full Text] [Related]
9. Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts.
Vázquez R; Licandro SA; Astorgues-Xerri L; Lettera E; Panini N; Romano M; Erba E; Ubezio P; Bello E; Libener R; Orecchia S; Grosso F; Riveiro ME; Cvitkovic E; Bekradda M; D'Incalci M; Frapolli R
Int J Cancer; 2017 Jan; 140(1):197-207. PubMed ID: 27594045
[TBL] [Abstract][Full Text] [Related]
10. Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.
Sciarrillo R; Wojtuszkiewicz A; El Hassouni B; Funel N; Gandellini P; Lagerweij T; Buonamici S; Blijlevens M; Zeeuw van der Laan EA; Zaffaroni N; Deraco M; Kusamura S; Würdinger T; Peters GJ; Molthoff CFM; Jansen G; Kaspers GJL; Cloos J; Giovannetti E
EBioMedicine; 2019 Jan; 39():215-225. PubMed ID: 30581150
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.
Abe S; Kaneko MK; Tsuchihashi Y; Izumi T; Ogasawara S; Okada N; Sato C; Tobiume M; Otsuka K; Miyamoto L; Tsuchiya K; Kawazoe K; Kato Y; Nishioka Y
Cancer Sci; 2016 Sep; 107(9):1198-205. PubMed ID: 27294401
[TBL] [Abstract][Full Text] [Related]
12. Schedule-dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and non-small cell lung cancer cell lines.
Nagai S; Takenaka K; Sonobe M; Wada H; Tanaka F
Chemotherapy; 2008; 54(3):166-75. PubMed ID: 18560222
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma.
Zucali PA; Perrino M; De Vincenzo F; Giordano L; Cordua N; D'Antonio F; Santoro A
Lung Cancer; 2020 Apr; 142():132-137. PubMed ID: 32102735
[TBL] [Abstract][Full Text] [Related]
14. Preclinical demonstration of synergistic Active Nutrients/Drug (AND) combination as a potential treatment for malignant pleural mesothelioma.
Volta V; Ranzato E; Martinotti S; Gallo S; Russo MV; Mutti L; Biffo S; Burlando B
PLoS One; 2013; 8(3):e58051. PubMed ID: 23526965
[TBL] [Abstract][Full Text] [Related]
15. MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma.
Yamamoto K; Seike M; Takeuchi S; Soeno C; Miyanaga A; Noro R; Minegishi Y; Kubota K; Gemma A
Oncol Rep; 2014 Dec; 32(6):2365-72. PubMed ID: 25231602
[TBL] [Abstract][Full Text] [Related]
16. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
Hoda MA; Pirker C; Dong Y; Schelch K; Heffeter P; Kryeziu K; van Schoonhoven S; Klikovits T; Laszlo V; Rozsas A; Ozsvar J; Klepetko W; Döme B; Grusch M; Hegedüs B; Berger W
Mol Cancer Ther; 2016 Oct; 15(10):2357-2369. PubMed ID: 27512118
[TBL] [Abstract][Full Text] [Related]
17. Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant Pleural Mesothelioma following Platinum plus Pemetrexed Chemotherapy: A Retrospective Study.
Koda Y; Kuribayashi K; Doi H; Kitajima K; Nakajima Y; Ishigaki H; Nakamura A; Minami T; Takahashi R; Yokoi T; Kijima T
Oncology; 2021; 99(3):161-168. PubMed ID: 33053560
[TBL] [Abstract][Full Text] [Related]
18. Gli as a novel therapeutic target in malignant pleural mesothelioma.
Li H; Lui N; Cheng T; Tseng HH; Yue D; Giroux-Leprieur E; Do HT; Sheng Q; Jin JQ; Luh TW; Jablons DM; He B
PLoS One; 2013; 8(3):e57346. PubMed ID: 23483902
[TBL] [Abstract][Full Text] [Related]
19. Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients.
Shukuya T; Takahashi T; Imai H; Tokito T; Ono A; Akamatsu H; Taira T; Kenmotsu H; Naito T; Murakami H; Endo M; Yamamoto N
Respir Investig; 2014 Mar; 52(2):101-6. PubMed ID: 24636265
[TBL] [Abstract][Full Text] [Related]
20. Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma.
Mairinger FD; Vollbrecht C; Flom E; Christoph DC; Schmid KW; Kollmeier J; Popper HH; Mairinger T; Walter RFH
Oncotarget; 2017 Jun; 8(23):37502-37510. PubMed ID: 28415584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
